Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group

NCT01117168 | Active Not Recruiting

• 3 other identifiers: ACCRN0710-C-0111100111
• Study Type: observational
• Target: 57,816
• Locations: 1 country
• Sites: 1

Brief Summary

The Children's Oncology Group has established a research network, the Childhood Cancer Research Network (CCRN), to collect information about children with cancer and other conditions that are benign but involve abnormal cell growth in order to help doctors and scientists better understand childhood cancer. The CCRN's goal is to collect clinical information about every child diagnosed with cancer and similar conditions in the United States and Canada, to allow researchers to study patterns, characteristics, and causes of childhood cancer. The information can also help researchers study the causes of childhood cancer. To expand the CCRN, parents of children who have been diagnosed with cancer will be asked to provide information about themselves and their child for research purposes.

Conditions

Pediatric Cancer; Leukemia; Sarcoma; Brain Tumors

Keywords

Children's Oncology Group; Pediatric Oncology; Pediatric Cancer; Registration; Leukemia; Brain Tumor; Sarcoma

Outcome Measures

Primary Outcomes (1)

• To collect information on children with cancer

  After initial diagnosis

Secondary Outcomes (1)

• To obtain consent to contact in the future for participation in future clinical trials

  At enrollment and at age of majority

Eligibility Criteria

• Age: Up to 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

Study Population

Pediatric and adolescent patients diagnosed with cancer

* All patients, diagnosed with a primary malignancy since the date the initial IRB approval was received for this study with any of the following diagnoses are eligible: * All cancer cases with an ICD-O histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant). * All lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant. * The benign/borderline conditions which will be reportable by agreement shall include: * Mesoblastic nephroma. * All teratomas, regardless of locations. * Myeloproliferative disease * Langerhans Cell histiocytosis * Patients with a secondary malignancy may be eligible provided they also meet the criteria in the above. These patients need to be enrolled using their primary diagnosis. * Participants 0 through 21 years of age are eligible; irrespective of eligibility for other COG studies. * Participant must be resident of the United States, Canada or Mexico.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Children's Oncology Group: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Children's Oncology Group

Arcadia, California, 91006, United States

Location

Related Publications (1)

• Ross JA, Severson RK, Pollock BH, Robison LL. Childhood cancer in the United States. A geographical analysis of cases from the Pediatric Cooperative Clinical Trials groups. Cancer. 1996 Jan 1;77(1):201-7. doi: 10.1002/(SICI)1097-0142(19960101)77:13.0.CO;2-7.

  PMID: 8630931 BACKGROUND

MeSH Terms

Conditions

Neoplasms; Leukemia; Sarcoma; Brain Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Hematologic Diseases; Hemic and Lymphatic Diseases; Neoplasms, Connective and Soft Tissue; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• Logan Spector

  STUDY CHAIR

• Susan Stork, CCRP

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 4, 2010
• First Posted: May 5, 2010
• Study Start: April 30, 2010
• Primary Completion (Estimated): December 31, 2030
• Study Completion (Estimated): December 31, 2030
• Last Updated: November 24, 2025

Record last verified: 2025-11

Locations

US (1)